

ARTICLE

Compound heterozygosity for two *MSH6* mutations in a patient with early onset of HNPCC-associated cancers, but without hematological malignancy and brain tumor

Jens Plaschke^{*1,6}, Michael Linnebacher^{2,6}, Matthias Kloor², Johannes Gebert², Friedrich W Cremer³, Sigrid Tinschert⁴, Daniela E Aust⁵, Magnus von Knebel Doeberitz² and Hans K Schackert¹

¹Department of Surgical Research, Dresden University of Technology, Dresden, Germany; ²Department of Molecular Pathology, Institute of Pathology, University of Heidelberg, Heidelberg, Germany; ³Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany; ⁴Department of Clinical Genetics, Dresden University of Technology, Dresden, Germany; ⁵Department of Pathology, Dresden University of Technology, Dresden, Germany

Heterozygous germline mutations in the human mismatch repair (MMR) genes *MLH1*, *PMS2*, *MSH2* and *MSH6* predispose to the hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Biallelic mutations in these genes have been reported for a limited number of cases resulting in hematological malignancies, brain tumors and gastrointestinal tumors early in childhood. These tumor phenotypes are frequently associated with café-au-lait spots (CALs), one of the clinical hallmarks of neurofibromatosis type 1 (NF1). We report the first case of compound heterozygosity for two *MSH6* mutations resulting in a nonconservative amino-acid change of a conserved residue and in a premature stop codon in a patient who developed rectal and endometrial cancer at ages 19 and 24 years, respectively, and presented few CALs in a single body segment. Immunohistochemistry and Western blotting revealed only residual expression of the *MSH6* protein in the normal cells. The disease history resembles the HNPCC phenotype rather than a phenotype associated with biallelic MMR gene mutations. Therefore, we assume that one or both mutations abolish protein function only partially, further supported by the parents, which are both carriers of one of the mutations each, and not affected by the disease at ages 57 and 58 years. Our data suggest considering biallelic mutations in MMR genes for patients who develop HNPCC-associated tumors at an unusually young age of onset, even without hematological or brain malignancies.

European Journal of Human Genetics (2006) 14, 561–566. doi:10.1038/sj.ejhg.5201568; published online 18 January 2006

Keywords: biallelic mutations; colorectal cancer; HNPCC; *MSH6*; mismatch repair

*Correspondence: Dr J Plaschke, Department of Surgical Research, Carl Gustav Carus Klinikum, Dresden University of Technology, Fetscherstrasse 74, D-01307 Dresden, Dresden, Germany. Tel: +49 351 458 3348; Fax: +49 351 458 5365; E-mail: plaschke@rcs.urz.tu-dresden.de

⁶These authors contributed equally to this work.

Received 15 August 2005; revised 11 October 2005; accepted 24 November 2005; published online 18 January 2006

Introduction

Heterozygous constitutional mutations of the mismatch repair (MMR) genes *MSH2*, *MSH6*, *MLH1* and *PMS2* predispose to hereditary nonpolyposis colorectal cancer (HNPCC, MIM 114500), an autosomal dominant cancer-susceptibility syndrome with high penetrance.^{1–2} Mutation carriers are at high risk to develop colorectal (CRC)

and endometrial cancer and are at increased risk to develop cancer of small bowel, stomach, ovary, ureter and hepatobiliary tract.³ A hallmark of these malignancies is contraction/expansion of simple sequence motifs termed microsatellite instability (MSI).⁴ Mutations in *MSH6* have been shown to account for 10–15% of all MMR gene mutations identified in families suspected of HNPCC.^{5,6} When compared to *MSH2* and *MLH1*, tumors occurring in *MSH6* mutation carriers (MIM no. 600678; GenBank accession: AH005068) are characterized by a lower frequency of instability at dinucleotide repeat markers.⁶ Clinically, these patients have a 10 years later age of tumor onset and a lower incidence of colorectal cancer, along with an increased incidence of endometrial cancer and other malignancies.^{5–9}

Biallelic MMR gene mutations have been reported for one or more patients of 14 families ($2 \times$ *MSH2*, $6 \times$ *MLH1*, $4 \times$ *PMS2*, $2 \times$ *MSH6*).^{10–12} A total of 11 homozygous mutations were present resulting from proven or suspected consanguineous mating in most of the families. Compound heterozygous mutations have been shown once for *MSH2* and twice for *PMS2*. In contrast to heterozygous MMR gene mutations, biallelic constitutional inactivation has been reported to result in the development of brain and colon tumors early in life, which is reminiscent of Turcot syndrome.¹³ Analogous to mouse models deficient in MMR, patients are at high risk to develop lymphomas, leukemia and gastrointestinal tumors early in life. In addition, they showed features of neurofibromatosis type 1 (NF1) such as café-au-lait spots (CALs, most patients), axillary freckling, Lisch nodules and neurofibromas (some patients), and tibial pseudarthrosis (one patient). Most patients with biallelic mutations in *MLH1* and *MSH2* died from hematological malignancies or brain tumors during the first decade of life.^{14–18} An exception constitutes the homozygous Arg687Trp mutation of *MLH1*, which was associated with colon and duodenal cancer at ages 9 and 11 years, respectively.¹⁹ In contrast, patients with biallelic mutations of *PMS2* and *MSH6* developed HNPCC-associated tumors (colon, rectum, duodenum, ovary) in addition to hematological malignancies and brain tumors, and tumor onset occurred primarily during the second and early third decade of life.^{10,13,20–22} This is the first report of a patient compound heterozygous for two *MSH6* mutations who lacks hematological malignancies and brain tumors.

Materials and methods

Patient data and material

The female patient HD3 had a rectal cancer diagnosed at age 19 years and endometrial cancer diagnosed at age 24 years, and is currently disease free at age 29 years after undergoing appropriate surgical therapy. She was recruited through the Bethesda guidelines (B2: individuals with two HNPCC-related cancers and B4: individuals with colorectal

or endometrial cancer diagnosed at age <45 years)²³ and was subsequently offered HNPCC diagnostics. The only recorded malignancy among her relatives was a rectal carcinoma affecting the paternal grand mother at age 73 years. Written informed consent was obtained from all family members investigated. The study was approved by the local ethics committee.

T cells were isolated from peripheral blood of the patient and her parents and activated using T-cell expander (Dyna, Oslo, Norway). Genomic DNA from peripheral blood and from T cells of the patient and her parents and from paraffin-embedded tumor tissue of the rectal carcinoma of the patient was extracted applying the QIAamp[®] blood and tissue kit (QIAGEN, Hilden, Germany). Messenger RNA was isolated from peripheral blood and from T cells of the patient and her parents applying the Quick-Prep *Micro* mRNA Purification Kit and reverse transcribed using the First-Strand cDNA Synthesis Kit (both Amersham Biosciences, Freiburg, Germany) according to manufacturer's protocol.

Immunohistochemistry

Immunohistochemical staining was performed for *MLH1*, *PMS2*, *MSH2* and *MSH6* on 5- μ m-thick, formalin-fixed, paraffin-embedded sections from both tumors of the patient as described previously.²⁴ Staining in the absence of the primary antibody served as negative controls. The normal staining pattern for all four antibodies was nuclear. The pattern of staining was examined by subjective assessment of two independent examiners (JP and DEA).

Western blotting

Cells used for Western blotting were grown in DMEM/F12 medium supplemented with 10% fetal calf serum (PAA, Cölbe, Germany). As controls, the colorectal carcinoma cell lines HCT116 (*MLH1*-deficient) and DLD-1 (*MSH6*-deficient) as well as the human B-cell precursor leukemia cell line NALM6 (*MSH2*-deficient) (all DSMZ, Braunschweig, Germany) and two B-cell lines from different individuals were used. Cell lysates were prepared under denaturing conditions, proteins were separated on denaturing 4–16% precast gradient SDS-polyacrylamide gels (Invitrogen, Karlsruhe, Germany) and blotted onto nitrocellulose membranes. After blocking in 5% skimmed milk in TBS/Tween for 1 h at room temperature, membranes were probed with anti-*MLH1* (Clone G168–15), anti-*MSH2* (Clone 27), or anti-*MSH6* (Clone 44; all antibodies were from BD Biosciences, Heidelberg, Germany). As a protein loading control, blots were also probed with anti-actin at 1:5000 (Oncogene, Schwalbach, Germany). As secondary antibody, we used horseradish peroxidase-conjugated anti-mouse Ig (1:1000, BD). All primary and secondary antibodies were diluted in blocking solution (5% skimmed milk powder, TBS/Tween) and were allowed to incubate for 1 h at room temperature. The immune complexes were

detected using the ECL-Kit (Amersham-Pharmacia, Freiburg, Germany).

Molecular analyses

Analysis for microsatellite instability (MSI) in tumor tissue was performed applying six mono- and nine polynucleotide repeat markers by multiplex amplification in five panels as described previously.²⁴ The markers include the National Cancer Institute/International Collaborative Group on HNPCC (NCI/ICG-HNPCC) reference marker panel for the evaluation of MSI in colorectal cancer (BAT25, BAT26, D2S123, D5S346, D17S250).²⁵

For mutation analysis, the entire coding sequence and flanking intronic regions of *MSH6* and *MSH2* were amplified and sequenced from genomic DNA, as described previously.²⁶ To examine mutations at the transcript level, RT-PCR analysis was performed using a sense primer located in exon 4 (GTE4S8: CGGAGGGATGTATCATTGAAG) and an antisense primer located in the 3' end of the gene (GTE10cA1: CCACCTTTGTCAGAAGTCAA).

Allele assignment of the two mutations was performed by amplification of an approximately 3.6 kb fragment containing both mutation sites (sense primer GTE5S located in intron 4: TATTTTGATGGGGGAGATCG and antisense primer GTE8del2A located in intron 9: ATAGTG-CATCATCCCTTCCC) applying the Expand Long Template PCR System (Roche Diagnostics, Mannheim, Germany) from genomic DNA and subsequent cloning into the plasmid vector pCR[®]2.1-TOPO[®] using the TOPO TA Cloning[®] Kit (Invitrogen, Karlsruhe, Germany). After transfection of competent bacteria cells (DH5 α) and overnight cultivation, 20 single clones were grown, plasmid DNA was isolated and subsequently inserts were sequenced from both ends.

Results

The female patient was recruited as part of our routine screening for potential HNPCC families/patients through the Bethesda guidelines. Microsatellite analysis revealed instability at 4/6 mono- and 2/8 polynucleotide markers for the rectal tumor. Initial results on immunohistochemistry of the rectal tumor were: no staining for *MSH6*, weak staining for *MSH2* and normal staining for *MLH1*. In addition, tumor-infiltrating lymphocytes did not stain for *MSH6*, which prompted us to conclude that staining of *MSH6* was not meaningful in this tumor. Sequence analysis of *MSH2* revealed no mutation, whereas a C-to-T transition at nucleotide 3226 of the *MSH6* gene was identified.⁶ The mutation results in the substitution of cysteine for arginine (amino acid 1076, exon 5), leading to a nonconservative change from a basic to a polar, uncharged residue. Arg1076 is conserved for the interdomain interaction among a wide variety of mutS homologs ranging from human to

bacteria.²⁷ Therefore, this mutation may have a role in carcinogenesis.

To further clarify the expression pattern of *MSH6* in normal cells, immunohistochemical analysis was repeated with normal colonic mucosa and with additional specimens of the rectal carcinoma, revealing lack of *MSH6* expression in tumor cells, in normal crypt cells and in tumor-infiltrating lymphocytes (Figure 1). Absence of MMR protein expression in normal and tumor cells occurs occasionally, likely due to insufficient conservation of the paraffin-embedded tumor specimen and is mirrored by failure of staining of other proteins. The absence of *MSH6* staining in tumor and normal cells, accompanied by normal staining of these proteins in other specimens in the same immunohistochemical series, indicate that the patient is completely or almost completely deficient for *MSH6*. This result was confirmed by Western blotting where T-cell extracts showed no signal for *MSH6* using conventional protocols and a residual expression with increased protein loading and extended exposure time (Figure 2). We cannot exclude some dominant negative effect of the missense mutation on protein expression as cells of the mother seem to have a weaker expression of *MSH6* than those of the father. Alternatively, it may simply represent different levels of activation and/or proliferation of the peripheral blood cells. Moreover, the mutation in exon 5 remains heterozygous in microdissected tumor DNA of two different specimens of the rectal tumor, basically excluding a second, somatic mutation in the form of allelic loss.

These results prompted us to evaluate the complete *MSH6* sequence. Sequencing of the coding region of *MSH6* including the flanking intronic regions and the promoter revealed a second C-to-T transition affecting nucleotide 3991, which changes codon 1331 (exon 9) from arginine to stop codon and is predicted to remove the last 30 residues from the protein. Cloning and sequencing of a PCR-amplified fragment containing both mutation sites assigned the mutations to separate alleles. Compound heterozygosity was verified upon availability of samples from the parents, whereby the nonsense mutation was inherited from the father and the missense mutation from the mother, both of which are healthy at ages 58 and 57 years, respectively.

RT-PCR from mRNA of the three family members and controls amplified a shortened transcript in addition to the full-length transcript, exclusively from the patient and her father, which both harbor the nonsense mutation in exon 9 (Figure 3). Sequence analysis of the cDNA amplicons revealed skipping of exon 9 giving rise to the shorter transcript. In addition, the patient's shorter transcript was wild type at the site of the missense mutation in exon 5, confirming that the skipping of exon 9 exclusively occurred in the allele harboring the nonsense mutation in exon 9. Both mutations were seen from the full-length




Figure 1 Expression of mismatch repair proteins, analyzed by immunostaining. (a–c) Tumor sections of patient HD3, harboring biallelic *MSH6* germline mutations, immunostained with MSH6-, MSH2- and MLH1 antibodies, respectively. There is no MSH6 staining in tumor and infiltrating normal cells, whereas MSH2 is expressed weakly and MLH1 normally. (d and e) A different tumor specimen stained for MSH6 and MSH2 in the same series of immunohistochemical analyses serves as a positive control. (f–h) Normal colonic mucosa of the patient also lacks MSH6 expression, whereas MSH2 and MLH1 are expressed in normal cells. Original magnification: $\times 200$.




Figure 2 Expression of mismatch repair proteins, analyzed by immunoblotting. (a) Western blotting revealed loss of MSH6 expression in normal T cells of patient HD3. Normal T cells of the parents express MSH6, albeit at a reduced level. The colorectal carcinoma cell lines HCT116 (MLH1-deficient) and DLD-1 (MSH6-deficient) as well as the human B-cell precursor leukemia cell line NALM6 (MSH2-deficient) and B-cell lines from two other individuals were used as controls. (b) To be able to finally decide whether there is a strong reduction or complete loss of MSH6 expression in normal cells of the patient, we repeated the Western blot analysis aiming at maximum sensitivity. Double amounts of protein (approximately 20 μ g) were loaded for the patient and her parents, the incubation time for MSH6 antibody was extended from 1 h to overnight and the time of exposure was prolonged from 3 to 30 min.

transcript of the patient indicating that the nonsense mutation in exon 9 only partially results in skipping of exon 9, and that the allele harboring the missense mutation in exon 5 is transcribed into mRNA.

Discussion

Homozygosity for a protein-truncating mutation in *MSH6* has been reported as associated with a strong phenotype in two affected siblings, one of whom was affected by lymphoma and CRC diagnosed at ages 5 and 8 years, respectively, and the other by glioblastoma multiforme diagnosed at age 8 years also showing CALS and axillary freckling.²⁸ Similar to the patient described here, parents were not affected and there was only one distant relative with CRC. Menko *et al*¹⁰ reported a child with oligodendroglioma at age 10 years and rectosigmoid cancer at age 12 years along with multiple CALS. The patient was homozygous for a 3 bp deletion in *MSH6* due to consanguineous mating. The mutation results in a two-by-one replacement of nonconserved amino acids and was not associated with loss of protein expression in normal cells. In contrast to both these and the majority of the other reported cases of biallelic MMR gene mutations, our patient had no hematological malignancy or brain tumor. Like the majority of reported cases, the patient had CALS, whereby the segmental pattern may be related to a




Figure 3 RT-PCR analysis from normal cells of the patient and her parents. RT-PCR analysis from T cells of the patient and her parents resulted in a shortened transcript from the patient and the father (both harboring the nonsense mutation in exon 9) in addition to the transcript of wild-type size. Sequencing of all fragments revealed skipping of exon 9 for the shortened transcripts, retention of heterozygosity at the exon 9 mutation site in the wild-type-sized transcripts from the patient and the father, and wild type for the exon 5 mutation site for the shortened transcript of the patient. The wild-type-sized transcripts from the patient and the mother were both heterozygous at the exon 5 mutation site. Therefore, skipping of exon 9 is a consequence of the nonsense mutation within this exon and both mutations do not or only partially affect stability of respective transcripts.




Figure 4 (a, b) Café-au-lait spots in the patient. Café-au-lait spots in patient HD3 are restricted to the area of the right lower costal arch.

diminished rather than a completely abolished MMR capacity (Figure 4). She had also suffered from *Lupus erythematosus*, although it is not known whether this disease condition is associated with MMR deficiency. Her disease history resembles a strong expression of the HNPCC phenotype but is milder than the phenotype described so far for biallelic MMR gene mutations. This may be explained by the potential hypomorphic nature (abolishing protein function only partially) of one or both mutations. Whereas no detectable *MSH6* expression was seen in the immunohistochemistry, Western blotting revealed a faint signal from normal cells of the patient. Therefore, we cannot exclude a residual activity of the

MSH6 protein. The transcript with the missense mutation in exon 5 and the transcript without exon 9 result in proteins with a changed amino acid, conserved for interdomain interaction, and one which lacks amino acids conserved for heterodimerization, respectively.²⁷ Both the lack of stable protein conformation and the lack of heterodimerization are likely to result in protein degradation. In contrast, the transcript of the paternal allele (nonsense mutation in exon 9) with retention of exon 9 is predicted to result in a protein lacking the last 30 amino acids, which are not conserved among MutS homologs. This transcript may be responsible for the residual expression of *MSH6*. Moreover, the two reported cases of biallelic MMR gene mutations nonassociated with hematological malignancies or brain tumors in early childhood constitute homozygous missense mutations (both affecting *MLH1*), whereby partially MMR function was observed for one of these mutations.^{11,19}

MSH6 mutations are associated with an approximately 10 years later age of disease onset and a lower incidence of colorectal cancer compared to *MLH1* or *MSH2* mutations.⁵⁻⁹ Therefore, families with *MSH6* mutations are less completely enrolled by the usually applied selection criteria for testing on MMR gene mutations like the Amsterdam criteria and the Bethesda guidelines. Assuming the participation of hypomorphic mutations resulting in a depleted rather than an abolished protein function, the phenotype associated with biallelic MMR gene mutations may resemble the spectrum of HNPCC-associated tumors at young age without hematological and brain malignancies. Indeed, we have identified in a different patient affected with colon cancer at age 31 years two *MSH6* mutations (p.C765W and p.V878A), proven to be biallelic (data not shown). The patient's mother, carrier of p.C765W, was affected with endometrial cancer at age 60 years. Two different mutations of the corresponding conserved residue of *MSH2* have been reported for HNPCC patients in the ICG-HNPCC mutation databank (<http://www.insight-group.org>). Amino acid change p.V878A does not affect a conserved residue, but has been identified in several patients suspected of HNPCC along with absence in normal control populations.^{5,7}

An unidentified second mutation in a family will leave family members tested negative for the identified first mutation with a deceptive certainty about their disease risk. Therefore, molecular diagnostics of MMR genes should comprise complete mutation analysis for patients with an unusually young age of disease onset according to the affected gene. In addition, aberrant protein expression in normal tissue and HNPCC-associated tumors in both parental branches may indicate a missed second mutation in HNPCC families. Moreover, as currently applied methods do not detect all possible mutations, relatives of such patients may not be excluded from the surveillance program if only one mutation was identified. More

stringent screening protocols have to be considered in cases with biallelic mutations, while less strict protocols on surveillance may be considered for relatives upon evidence of lower penetrance for a certain mutation.

Acknowledgements

We thank Ms M Reichmann and Ms A Colditz for excellent technical assistance. This work was supported by the Deutsche Krebshilfe grant 'Familiärer Darmkrebs' (70-2367-Scha2).

References

- de la Chapelle A: Genetic predisposition to colorectal cancer. *Nat Rev Cancer* 2004; **4**: 769–780.
- Peltomäki P, Vasen HF: Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. *Gastroenterology* 1997; **113**: 1146–1158.
- Lynch HT, Smyrk TC, Watson P *et al*: Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. *Gastroenterology* 1993; **104**: 1149–1535.
- Aaltonen LA, Peltomäki P, Leach FS *et al*: Clues to the pathogenesis of familial colorectal cancer. *Science* 1993; **260**: 812–816.
- Wijnen J, de Leeuw W, Vasen H *et al*: Familial endometrial cancer in female carriers of *MSH6* germline mutations. *Nat Genet* 1999; **23**: 142–144.
- Plaschke J, Engel C, Krüger S *et al*: Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic *MSH6* germline mutations compared with families with *MLH1* or *MSH2* mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium. *J Clin Oncol* 2004; **22**: 4486–4494.
- Berends MJ, Wu Y, Sijmons RH *et al*: Molecular and clinical characteristics of *MSH6* variants: an analysis of 25 index carriers of a germline variant. *Am J Hum Genet* 2002; **70**: 26–37.
- Peterlongo P, Nafa K, Lerman GS *et al*: *MSH6* germline mutations are rare in colorectal cancer families. *Int J Cancer* 2003; **107**: 571–579.
- Hendriks YM, Wagner A, Morreau H *et al*: Cancer risk in hereditary nonpolyposis colorectal cancer due to *MSH6* mutations: impact on counseling and surveillance. *Gastroenterology* 2004; **127**: 17–25.
- Menko FH, Kaspers GL, Meijer GA, Claes K, Van Hagen JM, Gille JJ: A Homozygous *MSH6* mutation in a child with cafe-au-lait spots, oligodendroglioma and rectal cancer. *Fam Cancer* 2004; **3**: 123–127.
- Raevaara TE, Gerdes AM, Lonnqvist KE *et al*: HNPCC mutation *MLH1* P648S makes the functional protein unstable, and homozygosity predisposes to mild neurofibromatosis type 1. *Genes Chrom Cancer* 2004; **40**: 261–265.
- Rey JM, Noruzinia M, Brouillet JP, Sarda P, Maudelonde T, Pujol P: Six novel heterozygous *MLH1*, *MSH2*, and *MSH6* and one homozygous *MLH1* germline mutations in hereditary nonpolyposis colorectal cancer. *Cancer Genet Cytogenet* 2004; **155**: 149–151.
- Hamilton SR, Liu B, Parsons RE *et al*: The molecular basis of Turcot's syndrome. *N Engl J Med* 1995; **332**: 839–847.
- Wang Q, Lasset C, Desseigne F *et al*: Neurofibromatosis and early onset of cancers in *hMLH1*-deficient children. *Cancer Res* 1999; **59**: 294–297.
- Ricciardone MD, Ozcelik T, Cevher B *et al*: Human *MLH1* deficiency predisposes to hematological malignancy and neurofibromatosis type 1. *Cancer Res* 1999; **59**: 290–293.
- Vilki S, Tsao JL, Loukola A *et al*: Extensive somatic microsatellite mutations in normal human tissue. *Cancer Res* 2001; **61**: 4541–4544.
- Whiteside D, McLeod R, Graham G *et al*: A homozygous germline mutation in the human *MSH2* gene predisposes to hematological malignancy and multiple cafe-au-lait spots. *Cancer Res* 2002; **62**: 359–362.
- Bougeard G, Charbonnier F, Moerman A *et al*: Early onset brain tumor and lymphoma in *MSH2*-deficient children. *Am J Hum Genet* 2003; **72**: 213–216.
- Gallinger S, Aronson M, Shayan K *et al*: Gastrointestinal cancers and neurofibromatosis type 1 features in children with a germline homozygous *MLH1* mutation. *Gastroenterology* 2004; **126**: 576–585.
- De Rosa M, Fasano C, Panariello L *et al*: Evidence for a recessive inheritance of Turcot's syndrome caused by compound heterozygous mutations within the *PMS2* gene. *Oncogene* 2000; **19**: 1719–1723.
- Trimbath JD, Petersen GM, Erdman SH, Ferre M, Luce MC, Giardiello FM: Cafe-au-lait spots and early onset colorectal neoplasia: a variant of HNPCC? *Fam Cancer* 2001; **1**: 101–105.
- De Vos M, Hayward BE, Picton S, Sheridan E, Bonthron DT: Novel *PMS2* pseudogenes can conceal recessive mutations causing a distinctive childhood cancer syndrome. *Am J Hum Genet* 2004; **74**: 954–964.
- Rodriguez-Bigas MA, Boland CR, Hamilton SR *et al*: A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: Meeting highlights and Bethesda guidelines. *J Natl Cancer Inst* 1997; **89**: 1758–1762.
- Plaschke J, Krüger S, Pistorius S, Theissig F, Saeger HD, Schackert HK: Involvement of *hMSH6* in the development of hereditary and sporadic colorectal cancer revealed by immunostaining is based on germline mutations, but rarely on somatic inactivation. *Int J Cancer* 2002; **97**: 643–648.
- Boland CR, Thibodeau SN, Hamilton SR *et al*: A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. *Cancer Res* 1998; **58**: 5248–5257.
- Plaschke J, Kruppa C, Tischler R *et al*: Sequence analysis of the mismatch repair gene *hMSH6* in the germline of patients with familial and sporadic colorectal cancer. *Int J Cancer* 2000; **85**: 606–613.
- Obmolova G, Ban C, Hsieh P, Yang W: Crystal structures of mismatch repair protein MutS and its complex with a substrate DNA. *Nature* 2000; **407**: 703–710.
- Hegde MR, Chong B, Blazo ME *et al*: A homozygous mutation in *MSH6* causes Turcot syndrome. *Clin Cancer Res* 2005; **11**: 4689–4693.